Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TAZ2 (Transcriptional adaptor zinc-binding domain 2) is a highly conserved zinc-binding helical domain within the CBP and p300 transcriptional coactivators. It stabilizes its structure using three zinc ions and acts as a promiscuous protein-protein interaction module, binding various transcription factors including p53, E2A, STAT1, p63, and p73 via disorder-to-order transitions of partner peptides[1][5][6]. TAZ2 exhibits autoinhibitory control of the HAT activity of CBP/p300; binding by transcription factors or genetic truncation can relieve its inhibition and activate acetyltransferase function, impacting histone acetylation and downstream transcriptional regulation[4]. Disease mutations leading to TAZ2 truncation are implicated in human cancer, and these cells show heightened vulnerability to histone deacetylase inhibitors, making TAZ2 functionally significant for transcriptional regulation and as a biomarker for therapeutic responsiveness[4].
In the context of cancer therapy: sensitization to histone deacetylase inhibition in cells with TAZ2-truncated p300/CBP
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcriptional adaptor zinc-binding domain 2 (TAZ2), found within CREB-binding protein (CBP) and E1A binding protein p300 (TAZ2).